1. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study
- Author
-
Wu,Xiaoning, Zhou,Jialing, Xie,Wen, Ding,Huiguo, Ou,Xiaojuan, Chen,Guofeng, Ma,Anlin, Xu,Xiaoyuan, Ma,Hui, Xu,Youqing, Liu,Xiaoqing, Meng,Tongtong, Wang,Lin, Sun,Yameng, Wang,Bingqiong, Kong,Yuanyuan, Ma,Hong, You,Hong, Jia,Jidong, Wu,Xiaoning, Zhou,Jialing, Xie,Wen, Ding,Huiguo, Ou,Xiaojuan, Chen,Guofeng, Ma,Anlin, Xu,Xiaoyuan, Ma,Hui, Xu,Youqing, Liu,Xiaoqing, Meng,Tongtong, Wang,Lin, Sun,Yameng, Wang,Bingqiong, Kong,Yuanyuan, Ma,Hong, You,Hong, and Jia,Jidong
- Abstract
Xiaoning Wu,1–3,* Jialing Zhou,1–3,* Wen Xie,4 Huiguo Ding,5 Xiaojuan Ou,1–3 Guofeng Chen,6 Anlin Ma,7 Xiaoyuan Xu,8 Hui Ma,9 Youqing Xu,10 Xiaoqing Liu,11 Tongtong Meng,1–3 Lin Wang,1–3 Yameng Sun,1–3 Bingqiong Wang,1–3 Yuanyuan Kong,1–3 Hong Ma,1–3 Hong You,1–3 Jidong Jia1–3 1Liver Research Centre, Beijing Friendship Hospital, Capital Medical University, Beijing, China; 2Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, Beijing, China; 3National Clinical Research Center of Digestive Diseases, Beijing, China; 4Liver Fibrosis Centre, Beijing Ditan Hospital, Capital Medical University, Beijing, China; 5Department of Digestive Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China; 6Liver Fibrosis Centre, Beijing 302 Hospital, Beijing, China; 7Department of Infectious Diseases, China-Japan Friendship Hospital, Beijing, China; 8Department of Infectious Diseases, Peking University First Hospital, Beijing, China; 9Liver Research Centre, Peking University People’s Hospital, Beijing, China; 10Department of Digestive Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; 11Department of Infectious Diseases, Peking Union Medical College Hospital, Beijing, China *These authors contributed equally to this work Background: De novo combination of lamivudine (Lam) and adefovir (Adv) was not rarely used in clinical practice. However, head-to-head comparisons of entecavir (Etv) monotherapy with this combination in hepatitis B virus (HBV)-related compensated cirrhosis patients are unavailable. This study aimed to compare the efficacy and safety of Etv monotherapy with combination therapy in patients with HBV-related compensated liver cirrhosis.Methods: Treatment-naïve patients with HBV-related compensated liver cirrhosis were recruited to receive either Etv monotherapy or a de novo combinati
- Published
- 2019